(NASDAQ: RYTM) Rhythm Pharmaceuticals's forecast annual revenue growth rate of 56.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Rhythm Pharmaceuticals's revenue in 2025 is $136,863,000.On average, 12 Wall Street analysts forecast RYTM's revenue for 2025 to be $11,231,861,910, with the lowest RYTM revenue forecast at $10,923,806,742, and the highest RYTM revenue forecast at $12,240,771,213. On average, 12 Wall Street analysts forecast RYTM's revenue for 2026 to be $19,460,663,098, with the lowest RYTM revenue forecast at $15,937,814,951, and the highest RYTM revenue forecast at $25,448,588,800.
In 2027, RYTM is forecast to generate $34,757,682,583 in revenue, with the lowest revenue forecast at $28,822,435,460 and the highest revenue forecast at $41,615,441,050.